TABLE 2.

Dupilumab Treatment Outcomes and Safety

MEDICATION USE PRE- AND POST-DUPILUMAB
MEDICATION USE	PRE-DUPILUMAB	POST-DUPILUMAB	P-VALUE
Daily H1 antagonist	27 (81.8%)	20 (60.1%)	0.03
Total # of daily antihistamines, mean±SD	1.95 ± 2.0	0.13 ± 0.20	0.01
Daily oral corticosteroids	2 (6%)	1 (3%)	0.32
LTRA	11 (33.3%)	9 (27.3%)	0.8
H2 antagonist	5 (15.2%)	3 (9.1%)	0.32
Cyclosporine	1 (3%)	1 (3%)	1.0
Omalizumab*	6 (18.2%)	3 (9.1%)	0.18
PHYSICIAN GLOBAL IMPRESSION OF CHANGE
ASSESSMENT	MILD (N=20)	MODERATE/ SEVERE (N=13)	P-VALUE
Worse	1 (5.0%)	1 (7.9%)	0.02
Unchanged	13 (65.0%)	2 (15.4%)	0.02
Improved	6 (30%)	10 (77%)	0.02
TREATMENT EMERGENT ADVERSE EVENTS
ADVERSE EVENT (n=33)		FREQUENCY (%)
None		26 (78.8%)
Anaphylaxis		1 (3%)
Arthralgias		3 (9.1%)
Conjunctivitis		2 (6.1%)
CSU recurrence on Dupilumab		1 (3%)
Injection Site Redness/ Irritation		0 (0%)

^*Within 30 days of starting Dupilumab. LTRA: leukotriene receptor antagonist